Boston Scientific provides funding for MValve Technologies

Boston Scientific announced on Oct. 8 that it had provided additional financing for MValve Technologies, a company that is developing a percutaneous mitral valve replacement system.

Boston Scientific said it has an exclusive option to acquire MValve Technologies, a privately held corporation founded in 2011 with operations in San Diego and Herezeliya, Israel.

MValve Technologies, which has received funding from Boston Scientific since 2012, plans to use some of the new financing to fund a trial for the MValve docking system for transcatheter mitral valve replacement in patients with mitral regurgitation.

With that approach, Boston Scientific’s Lotus valve is deployed inside the MValve docking system, which is not available for sale. The approach is intended to treat mitral regurgitation, the most common type of heart valve disorder.

The Lotus aortic valve system is not FDA-approved and is not available for sale in the U.S., but it is approved in Europe. The system includes a pre-loaded, stent-mounted tissue valve prosthesis and catheter delivery system for guidance and percutaneous placement of the valve.

On Oct. 5, MValve Technologies announced the first human implantation of its docking system and the Lotus valve was completed successfully in a 72 year old man with valve disease at the University Clinic in Bonn, Germany.

Maurice Buchbinder, MD, an interventional cardiologist and founder and medical director of MValve Technologies, was present at the procedure.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup